Robert Christopher Andrade Purchases 8,220 Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) Stock
Robert Christopher Andrade, a Senior Officer at Fennec Pharmaceuticals Inc. (TSE:FRX), purchased 8,220 shares of the company's stock on June 2nd at an average price of C$6.99 per share, totaling C$57,433.14. Following this transaction, Fennec's stock rose by 1.5%, reaching C$11.33. The company has a market cap of C$218.50 million and a P/E ratio of -191.93. Fennec Pharmaceuticals specializes in biopharmaceuticals, particularly in pediatric oncology.
Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Senior Officer Robert Christopher Andrade bought 8,220 shares of the company's stock in a transaction on Monday, June 2nd. The stock was bought at an average cost of C$6.99 per share, for a total transaction of C$57,433.14.
Get Fennec Pharmaceuticals alerts:
Fennec Pharmaceuticals Trading Up 1.5%
FRX stock traded up C$0.17 during mid-day trading on Wednesday, reaching C$11.33. 136 shares of the stock traded hands, compared to its average volume of 1,205. The stock's fifty day moving average is C$8.64 and its 200-day moving average is C$8.81. The company has a market cap of C$218.50 million, a P/E ratio of -191.93 and a beta of 0.25. Fennec Pharmaceuticals Inc. has a 52-week low of C$5.65 and a 52-week high of C$11.68. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83.
About Fennec Pharmaceuticals
(Get Free Report)Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Further Reading
- Five stocks we like better than Fennec Pharmaceuticals
- Golden Cross Stocks: Pattern, Examples and Charts
- Guidewire Rockets Higher: A Move Above $300 Is Probable
- How to Capture the Benefits of Dividend Increases
- Analog Devices' Cyclical Recovery Story Has Just Begun
- 3 Tickers Leading a Meme Stock Revival
- Joby's Saudi MoU: Strong Initial Reaction Meets Market Dynamics
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Fennec Pharmaceuticals Right Now?
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
